Intuitive (NASDAQ: ISRG) continues to get back to its roots, claiming a European approval for its da Vinci 5 system in minimally invasive cardiac procedures.
In a study published in Cancer Discovery, cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells.
Researchers at the Fraunhofer Institute for Integrated Circuits IIS and the Technical University of Dresden have tested a new approach for investigating disease-related changes in body odor. Using laser-based photoacoustic spectroscopy, they analyzed volatile organic compounds in simple body swabs. An initial study revealed differences between samples from healthy individuals and those from people with Parkinson’s disease, COVID-19, and other diseases. The results, published in Scientific Reports, demonstrate the method’s potential for faster preliminary screenings in the future.
Rutgers engineers have developed a smart shoe that automatically analyzes how a person walks, a technology that someday could help monitor people with Parkinson’s disease, spinal cord injuries, traumatic brain injuries and other movement disorders. The prototype analyzes movement with 95.4% accuracy while counting steps and estimating calories burned.
Research published today in Cell identifies three small subclusters of cells that drive pancreatic cancer-induced cachexia, a muscle-wasting and fat-loss condition that makes patients less able to tolerate cancer treatment. The study, led by the University of Oklahoma, could help researchers develop treatments targeting these subclusters.
The adult human heart is a reliable, resilient engine fueling our everyday lives while also being responsive enough to supercharge a Usain Bolt sprint or sustain a three-week bike race in the French Alps and Pyrenees.
Developed to fit around nursing workflows, ClinicalKey Nursing AI gives nurses fast, traceable answers to clinical questions at the point of care.
SEOUL, South Korea, Sept. 29, 2026 /PRNewswire/ — Yuyu Teijin Medicare, a home healthcare joint venture between Yuyu Pharma of Korea and Teijin Pharma of Japan, has completed a pilot delivery of medical supplies by drone to a ventilator patient living on a remote Korean island.
U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) underscore UTRxMYCN M1-14’s therapeutic targeting of the “undruggable” MYCN (N-MYC) in rare, aggressive soft tissue sarcomas, addressing a significant unmet clinical need in pediatric and adult sarcomas.
Mobile platform combines smartphone technology, a proprietary light-occluding headset, and AI-assisted software to capture and analyze nystagmus without complex equipment.